CONEXUS MEDSTAFF HOLDING COMPANY LIMITED

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -3.6%

  £34,148,887 → £32,935,038

• Cash

  -53.4%

  £10,039,577 → £4,674,966

• Net assets

  -5.9%

  £18,568,231 → £17,469,730

• Employees

  +1.7%

  362 → 368

• Operating profit

  -173.9%

  £1,279,460 → -£945,466

• Profit before tax

  -169%

  £1,275,889 → -£880,470

• Wages

  -1.2%

  £24,023,082 → £23,723,428

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. CONEXUS MEDSTAFF HOLDING COMPANY LIMITED 2022-01-18 → present
2. BRABCO 2103 LIMITED 2021-06-23 → 2022-01-18

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Cooper Parry Group Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. CONEXUS MEDSTAFF HOLDING COMPANY LIMITED · parent
   1. Conexus Medstaff Limited 100% · UK
   2. US Medstaff Holding Company LLC 100% · USA
   3. Conexus Medstaff LLC 100% · USA

Significant events

• “In May 2023, retrogression occurred, halting visa processing for applications submitted after December 2021.”
• “In 2022, Conexus MedStaff submitted visas via the H1B Lottery which can be run in parallel to the green card process... Over the last 3 years Conexus MedStaff has filed an increasing number of visa petitions following lottery approval with a record amount during 2024, up 13% on 2023.”
• “During 2022, Conexus MedStaff strategically initiated an NCLEX sponsorship program to deliver a unique supply of candidates into its global talent acquisition. In 2024, Conexus MedStaff increased the overall number of visa applications with 35% of visa applications relating to nurses who have been internally sponsored.”
• “In 2024, Conexus MedStaff recorded revenue of $44.1 million, representing a modest 4% decline on the previous year, though still 15% ahead of 2022.”
• “Revenue from Medical Technologists rose sharply to $11.0 million, a remarkable 309% increase on 2023, highlighting the strong momentum in this emerging area. While RN revenue declined by 23% year-on-year and 14% compared to 2022.”
• “The company posted a small operating loss of $14,430 before amortisation in 2024, reflecting deliberate investment in strengthening the clinician pipeline.”
• “Internally, in Q4 there was execution of a strategic plan to align capacity to business needs and performance, leveraging global resource pools across the company footprint. Simultaneously, internal investment in systems via an ambitious digital transformation program will determine a scalable platform for business operations to support future measurable success.”
• “In 2024, Visa applications soared, with the volume of applications more than the prior 5 years combined due to increased talent acquisition supply supported by the sponsorship program and the additional MTs line of business.”
• “The Contract Asset, which reflects investment in the clinician supply chain, increased by $1.6 million in 2024 to reach $5.6 million.”
• “During 2024, Conexus MedStaff paid $163,004 in relation to audit with $91,229 paid in 2023.”
• “Subsequent to the year end, Conexus Medstaff LLC was named in a class and collective action lawsuit alleging various claims concerning employment practices, worker protections and employment regulation.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.